MXPA05008988A - Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi) ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis. - Google Patents

Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi) ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis.

Info

Publication number
MXPA05008988A
MXPA05008988A MXPA05008988A MXPA05008988A MXPA05008988A MX PA05008988 A MXPA05008988 A MX PA05008988A MX PA05008988 A MXPA05008988 A MX PA05008988A MX PA05008988 A MXPA05008988 A MX PA05008988A MX PA05008988 A MXPA05008988 A MX PA05008988A
Authority
MX
Mexico
Prior art keywords
acetic acid
acid derivatives
cyclohexylmethoxy
oxazol
arteriosclerosis
Prior art date
Application number
MXPA05008988A
Other languages
English (en)
Spanish (es)
Inventor
Falk Eugene
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA05008988A publication Critical patent/MXPA05008988A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
MXPA05008988A 2003-02-27 2004-02-19 Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi) ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis. MXPA05008988A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001579 WO2004076427A1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
MXPA05008988A true MXPA05008988A (es) 2005-10-18

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
MXPA05008951A MXPA05008951A (es) 2003-02-27 2004-02-19 Derivados de acido 3-metil -2-(3- (2-fenil -oxazol-4 -ilmetoxi) -ciclohexanocarbonil -aminobutirico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
MXPA05008995A MXPA05008995A (es) 2003-02-27 2004-02-19 Derivados de acido 4 - (3-(2-feniloxazol - 4 - ilmetoxi) ciclohexiloxi) - butanoico y compuestos relacionados como moduladores de ppar para tratar la diabetes tipo 2 y la aterosclerosis.
MXPA05008988A MXPA05008988A (es) 2003-02-27 2004-02-19 Derivados de acido 3-(2-fenil-oxazol-4-ilmetoxi) ciclohexilmetoxiacetico y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MXPA05008951A MXPA05008951A (es) 2003-02-27 2004-02-19 Derivados de acido 3-metil -2-(3- (2-fenil -oxazol-4 -ilmetoxi) -ciclohexanocarbonil -aminobutirico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
MXPA05008995A MXPA05008995A (es) 2003-02-27 2004-02-19 Derivados de acido 4 - (3-(2-feniloxazol - 4 - ilmetoxi) ciclohexiloxi) - butanoico y compuestos relacionados como moduladores de ppar para tratar la diabetes tipo 2 y la aterosclerosis.

Country Status (34)

Country Link
US (5) US7365084B2 (US07259177-20070821-C00071.png)
EP (3) EP1599452B1 (US07259177-20070821-C00071.png)
JP (3) JP2006519193A (US07259177-20070821-C00071.png)
KR (3) KR20050106461A (US07259177-20070821-C00071.png)
CN (3) CN100398526C (US07259177-20070821-C00071.png)
AR (3) AR043432A1 (US07259177-20070821-C00071.png)
AT (3) ATE435217T1 (US07259177-20070821-C00071.png)
AU (3) AU2004215672B2 (US07259177-20070821-C00071.png)
BR (3) BRPI0407907A (US07259177-20070821-C00071.png)
CA (3) CA2517381A1 (US07259177-20070821-C00071.png)
CL (2) CL2004000391A1 (US07259177-20070821-C00071.png)
CO (2) CO5690578A2 (US07259177-20070821-C00071.png)
DE (4) DE10308355A1 (US07259177-20070821-C00071.png)
DK (3) DK1599453T3 (US07259177-20070821-C00071.png)
EC (2) ECSP055985A (US07259177-20070821-C00071.png)
ES (3) ES2326418T3 (US07259177-20070821-C00071.png)
HR (3) HRP20050744A2 (US07259177-20070821-C00071.png)
IL (2) IL170316A (US07259177-20070821-C00071.png)
MA (3) MA27737A1 (US07259177-20070821-C00071.png)
MX (3) MXPA05008951A (US07259177-20070821-C00071.png)
NO (3) NO20054396L (US07259177-20070821-C00071.png)
OA (2) OA13034A (US07259177-20070821-C00071.png)
PA (1) PA8596801A1 (US07259177-20070821-C00071.png)
PE (3) PE20050292A1 (US07259177-20070821-C00071.png)
PL (3) PL378130A1 (US07259177-20070821-C00071.png)
PT (3) PT1599453E (US07259177-20070821-C00071.png)
RS (1) RS20050594A (US07259177-20070821-C00071.png)
RU (3) RU2005130002A (US07259177-20070821-C00071.png)
SA (1) SA04250153A (US07259177-20070821-C00071.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00071.png)
TW (3) TW200500349A (US07259177-20070821-C00071.png)
UY (2) UY28210A1 (US07259177-20070821-C00071.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00071.png)
ZA (2) ZA200505765B (US07259177-20070821-C00071.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CN101505778B (zh) 2006-08-10 2012-09-05 株式会社mimozax 含有来自金合欢属树皮的物质的降血糖组合物
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
DK2246343T3 (en) 2008-02-29 2016-08-15 Nissan Chemical Ind Ltd Process for the preparation of thiophene compound and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
MX2020006252A (es) 2017-12-13 2020-09-07 Canon Kk Cartucho y aparato de formacion de imagen.
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP3071832B2 (ja) 1996-01-17 2000-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合した1,2,4−チアジアジン及び縮合した1,4−チアジン誘導体、これらの製造および使用
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP0958296B1 (en) 1996-12-31 2003-07-30 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
EP1067109B1 (en) * 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
RU2278860C2 (ru) * 1999-04-28 2006-06-27 Санофи-Авентис Дойчланд Гмбх Производные триарил-содержащих кислот в качестве лигандов рецепторов ппар
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト
JP4792186B2 (ja) 1999-09-01 2011-10-12 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
AU773777B2 (en) 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
EP2266665B1 (en) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
PL365533A1 (en) 2000-04-25 2005-01-10 Kyorin Pharmaceutical Co, Ltd. Novel stable crystal of thiazolidinedione derivative and process for producing the same
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
BR0111457A (pt) 2000-06-09 2003-06-24 Aventis Pharma Deustschland Gm Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
PT1313716E (pt) * 2000-08-23 2007-07-11 Lilly Co Eli Derivados do ácido oxazolil-arilpropiónico e a sua utilização como agonistas do ppar
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
RS50864B (sr) 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
CN100357280C (zh) * 2000-12-25 2007-12-26 小野药品工业株式会社 二氢化萘衍生物及包含该衍生物作为活性成分的药物
WO2002064549A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EP1401434B1 (en) * 2001-06-07 2006-11-15 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
PL208515B1 (pl) 2001-08-31 2011-05-31 Sanofi Aventis Deutschland Pochodne diarylocykloalkilowe, środki lecznicze zawierające te związki oraz ich zastosowanie jako aktywatorów PPAR
ATE433440T1 (de) 2002-02-05 2009-06-15 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
DK1599455T3 (da) 2009-11-09
OA13035A (en) 2006-11-10
PL378130A1 (pl) 2006-03-06
MXPA05008995A (es) 2005-10-18
JP2006519194A (ja) 2006-08-24
US20040209920A1 (en) 2004-10-21
TNSN05206A1 (en) 2007-06-11
RU2005130002A (ru) 2006-01-27
DK1599453T3 (da) 2009-08-24
EP1599452B1 (de) 2007-06-20
CA2517386A1 (en) 2004-09-10
ATE435217T1 (de) 2009-07-15
OA13034A (en) 2006-11-10
WO2004076426A1 (de) 2004-09-10
CN1753881A (zh) 2006-03-29
EP1599453B1 (de) 2009-05-06
DE502004004139D1 (de) 2007-08-02
SA04250153A (ar) 2005-12-03
UY28209A1 (es) 2004-09-30
JP2006519193A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
US7259177B2 (en) 2007-08-21
EP1599455A1 (de) 2005-11-30
ES2326418T3 (es) 2009-10-09
MXPA05008951A (es) 2005-11-04
BRPI0407758A (pt) 2006-02-14
AR043427A1 (es) 2005-07-27
PT1599452E (pt) 2007-09-12
RU2005129992A (ru) 2006-02-10
MA27736A1 (fr) 2006-02-01
TNSN05204A1 (en) 2007-06-11
TW200508210A (en) 2005-03-01
PT1599453E (pt) 2009-07-14
ZA200505765B (en) 2006-05-31
HRP20050744A2 (en) 2006-09-30
DK1599452T3 (da) 2007-10-01
DE502004009453D1 (de) 2009-06-18
CN100398526C (zh) 2008-07-02
CN100439345C (zh) 2008-12-03
CN1753879A (zh) 2006-03-29
ATE365159T1 (de) 2007-07-15
US20080167354A1 (en) 2008-07-10
UY28210A1 (es) 2004-09-30
ZA200505768B (en) 2005-11-23
CA2516620A1 (en) 2004-09-10
CO5690580A2 (es) 2006-10-31
ES2287700T3 (es) 2007-12-16
AR043433A1 (es) 2005-07-27
CO5690578A2 (es) 2006-10-31
WO2004076428A1 (de) 2004-09-10
CA2517381A1 (en) 2004-09-10
NO20054408D0 (no) 2005-09-22
KR20050106461A (ko) 2005-11-09
CL2004000392A1 (es) 2005-04-22
CL2004000391A1 (es) 2005-01-07
ATE430738T1 (de) 2009-05-15
EP1599453A1 (de) 2005-11-30
NO20054398D0 (no) 2005-09-22
HRP20050742A2 (en) 2006-09-30
US20050215596A1 (en) 2005-09-29
ES2329366T3 (es) 2009-11-25
JP2006519199A (ja) 2006-08-24
PL378437A1 (pl) 2006-04-03
US20080015238A1 (en) 2008-01-17
AU2004215677B2 (en) 2010-01-07
KR20050106462A (ko) 2005-11-09
MA27742A1 (fr) 2006-02-01
US20050101637A1 (en) 2005-05-12
US7365084B2 (en) 2008-04-29
AR043432A1 (es) 2005-07-27
PE20050292A1 (es) 2005-05-24
RU2005129995A (ru) 2006-01-27
PL377735A1 (pl) 2006-02-20
BRPI0407907A (pt) 2006-02-14
ECSP055985A (es) 2006-01-16
PE20050293A1 (es) 2005-05-24
AU2004215672A1 (en) 2004-09-10
ECSP055986A (es) 2006-01-16
BRPI0407814A (pt) 2006-02-14
NO20054398L (no) 2005-11-02
AU2004215677A1 (en) 2004-09-10
WO2004076427A1 (de) 2004-09-10
IL170314A (en) 2010-11-30
RS20050594A (en) 2007-12-31
PT1599455E (pt) 2009-09-29
MA27737A1 (fr) 2006-02-01
CN1756748A (zh) 2006-04-05
EP1599455B1 (de) 2009-07-01
AU2004215672B2 (en) 2010-01-07
NO20054396L (no) 2005-11-11
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
KR20050105492A (ko) 2005-11-04
US7872034B2 (en) 2011-01-18
NO20054396D0 (no) 2005-09-22
TW200510352A (en) 2005-03-16
PE20040959A1 (es) 2005-01-17
DE10308355A1 (de) 2004-12-23
AU2004215673A1 (en) 2004-09-10
AU2004215673B2 (en) 2009-10-01
DE502004009690D1 (de) 2009-08-13
EP1599452A1 (de) 2005-11-30
TW200500349A (en) 2005-01-01
CN100439347C (zh) 2008-12-03

Similar Documents

Publication Publication Date Title
TNSN05204A1 (en) 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
RS20050019A (en) Heterocyclically substituted benzoylureas,method for their production and their use as medicaments
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
UA104987C2 (uk) Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MXPA04001850A (es) Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilizacion como agentes activadores de ppar.
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2005116003A3 (de) Substituierte oxazol-benzoisothiazoldioxidderivate, verfahren zu deren herstellung und deren verwendung
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
NO20054381L (no) 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
NO20054168L (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2008023004A8 (de) Enantiomerenreine betaagonisten, verfahren zu deren herstellungen und deren verwendung als arzneimittel
NO20063860L (no) 7-fenylamino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav samt deres anvendelse som legemidler
TWI256952B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
MXPA05009054A (es) Derivados de arilcicloalquilo con cadenas laterales ramificadas en calidad de moduladores de receptores ppar, metodo para su produccion y su uso como medicamentos.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration